Table 3 Clinical trials of M2-based vaccines
From: M2e-based universal influenza vaccines: a historical overview and new approaches to development
Company (country) | Phase | Year | Clinicaltrials.gov identifier | Available results |
|---|---|---|---|---|
VaxInnate (USA) | I | 2007–2008 | NCT00603811 | No |
Sanofi (France) | I | 2007–2009 | NCT00819013 | Yes |
VaxInnate (USA) | I | 2009 | NCT00921206 | Yes [123] |
VaxInnate (USA) | II | 2009–2011 | NCT00921947 | Yes |
VaxInnate (USA) | I/ II | 2009–2010 | NCT00921973 | Yes [117] |
Imutex Limited (United Kingdom) | I | 2010 | NCT01181336 | No |
GeneOne Life Science (Republic of Korea) | I | 2010–2012 | NCT01184976 | No |
Theraclone Sciences (USA) | I | 2012 | NCT01390025 | Yes [99] |
II | 2012 | NCT01719874 | ||
VA Pharma LLC (Russian Federation) | I | 2018 | NCT03789539 | No |